CTOR · Citius Oncology, Inc.
$0.74
-0.02 (-2.02%)
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to support our operations beyond November 2026, which raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$69.16M
Shares
92.98M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jonathan Peri | Class I member of the Board | Appointed | 2026-08-12 |
| Joel Mayersohn | Class I director | Appointed | 2025-10-27 |
| Myron Holubiak | Class I director | Appointed | 2025-10-27 |